Avalo Therapeutics AVTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$84.74M-216% | -$78.26M-123% | -$99.88M-1,155% | -$46.22M-27.6% | $73.01M+151% | ||
| $226K-16.3% | $344K+104% | $396K+175% | $371K+146% | $270K+69.8% | ||
| $13.96M+64.9% | $13.62M+133% | $12.02M+223% | $10.71M+279% | $8.46M+160% | ||
| $169K+47.0% | $165K+44.7% | $148K— | $124K— | $115K— | ||
| -$325K-38.3% | -$146K+10.4% | -$1.34M-231% | $1.71M+1,378% | -$235K+95.0% | ||
| $6.87M— | $6.66M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$59.69M-14.1% | -$51.46M-4.9% | -$52.26M-42.1% | -$47.42M-47.8% | -$52.31M-95.0% | ||
| —— | —— | —— | —— | —— | ||
| -$58.62M— | -$84.12M— | —— | —— | —— | ||
| $16.94M— | $14.76M— | $40K— | $40K— | —— | ||
| $1.29M— | $510K— | $510K— | $509K— | —— | ||
| $15.99M— | $14.59M— | $81.61M— | —— | —— | ||
| -$99.92M— | -$118.59M— | -$54.77M— | —— | —— | ||
| $796K— | $690K— | $493K— | —— | —— | ||
| -$8.66M-224% | -$8.76M-176% | $6.25M+7.0% | -$5.18M-214% | -$2.67M-305% | ||
| —— | $0-100% | $77.25K-66.7% | $154.5K0.0% | $231.75K+200% | ||
| -$125K— | -$87K— | -$31K— | —— | —— | ||
| $6.87M— | $6.66M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $433.5K— | $867K— | $1.3M— | ||
| —— | $462K— | $346.5K— | $231K— | $115.5K— | ||
| —— | $0-100% | $17.34M-66.7% | $34.69M0.0% | $52.03M+200% | ||
| $509K— | $0— | —— | —— | —— | ||
| —— | $0-100% | $78K-66.7% | $156K0.0% | $234K+200% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Avalo Therapeutics generate?
- Avalo Therapeutics (AVTX) generated -$59.7M in operating cash flow over the trailing twelve months.
- Where does Avalo Therapeutics's cash flow data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
